Why is the World of Orphan Haemato-Oncology Agents Changing?As an increasing number of targeted oncology and haematology products are getting approved by EMA and FDA, the orphan space is becoming more and more crowded in these therapeutic areas.Patients with a
Kinesys Consulting Ltd is pleased to announce that the European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to SGX301(synthetic hypericin) for the treatment of
Kinesys' CEO Gerry McGettigan will present on Regulatory & Commercial aspects of Biosimilars at the SMi Conference on 16 November 2015, Renaissance Woodbridge Hotel, Iselin, New Jersey. On 17 November, Gerry and Kinesys' Product Development Expert Graeme Deuchar will hold an interactive workshop
Kinesys' Gerry McGettigan and Oncobiologics' Liz Yamashita give their views on changes in regulatory and commercial aspects of Biosimilars affecting Asia, Europe and USA. To Download the Article - Click here
Kinesys delivered a Presentation labelled "Biosimilars Clinical & Regulatory Strategies Encompassing the Needs of East to West" during a visit to Suzhou, China in November 2014. To Download the Presentation - Click Here
